|Articles|December 9, 2021
- Pharmaceutical Executive-12-01-2021
- Volume 41
- Issue 12
Pharmaceutical Executive, December 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive December 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 4 years ago
New Bespoke Gene Therapy Consortium Is Welcome Developmentalmost 4 years ago
2022 Pipeline Report: Capitalizing on Opportunityalmost 4 years ago
Oncology Optimistalmost 4 years ago
What Does the Future Hold for Biopharma in 2022?almost 4 years ago
Playing the Long Game on Tighter Than Label Coveragealmost 4 years ago
Real-World Problems for Real-World Data Guidance?almost 4 years ago
Looking Back at Our Leadership Lessons From the Past Yearalmost 4 years ago
IP and Pharmaceutical Trade: Europe’s Unresolved Debatealmost 4 years ago
Pandemic Alters Policies and Practices for Drug DevelopmentNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
3
Report: Richard Pazdur Out as Director of CDER
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
